AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Friday 20 November 2026
News from the 24 hours to Friday morning, 20 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by the FDA granting priority review to AstraZeneca's sonesitatug vedotin for gastric cancer, which is clearly positive. New collaborations in oncology and lupus added to the good tone, though a share price fall and cautious technical commentary tempered it.
What drove it
- FDA priority review
- Tempus AI partnership
- share price fall
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 14 Nov | +5.5 | 39 |
| Sun 15 Nov | +7.5 | 9 |
| Mon 16 Nov | +4.5 | 6 |
| Tue 17 Nov | +9.7 | 45 |
| Wed 18 Nov | +7.0 | 29 |
| Thu 19 Nov | +5.5 | 23 |
| Fri 20 Nov | +8.0 | 19 |
4 stories · 19 headlines · strongest first
Pharma and healthcare on 20 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Sone-Ve, AstraZeneca's gastric cancer drug, receives priority review from the FDA +9.413 headlines today · The FDA accepted the BLA for sonesitatug vedotin with priority review for CLDN18.2-positive gastric cancers. | ||
| +10.0 | Regulator fast-tracks cancer drug backed by strong survival benefit. | |
| +9.7 | Accelerated regulatory review granted for gastric cancer therapy. | |
| +9.5 | US regulator expedites review of cancer drug. | |
| +9.5 | US regulator gives faster review to gastric cancer candidate. | |
| +9.5 | Gastric cancer medicine receives accelerated US regulatory review. | |
| +9.5 | Official announcement of accelerated US review for gastric cancer drug. | |
| +9.3 | Quick regulatory review for targeted gastric cancer treatment. | |
| +9.3 | Gastric cancer drug obtains accelerated US regulatory review. | |
| +9.3 | Company announces accelerated US review of its application. | |
| +9.3 | Share-focused coverage of accelerated regulatory review for cancer drug. | |
| +9.2 | Licence application accepted for expedited US assessment. | |
| +9.2 | Licence application accepted with accelerated review status. | |
| +8.3 | Company pursuing American approval for gastric cancer treatment. | |
| AstraZeneca pledges $200m to Tempus AI as their agreement is extended +4.62 headlines today · 12 in all, since 19 November · AstraZeneca extended its Tempus AI partnership with a $200m commitment. | ||
| +5.8 | Extended data and AI oncology partnership with sizeable financial commitment. | |
| +5.0 | Partnership extended with large spending pledge; analyst valuation caveat. | |
| AstraZeneca share price moves −1.92 headlines today · 4 in all, since 19 November · Pieces report AstraZeneca down 2.51% and downside momentum. | ||
| −5.8 | Share price dropped notably during the trading day. | |
| −4.2 | Technical view says weak price momentum continues, though support holds. | |
| AstraZeneca collaborates with Lupus Research Alliance +5.52 headlines today · AstraZeneca has entered a partnership with Lupus Research Alliance and Lupus Therapeutics to develop lupus drugs. | ||
| +5.5 | New research tie-up aimed at developing lupus treatments. | |
| +5.5 | Lupus organisations partner with company on drug development. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.